ACT for Chronic Wound Healing in India: When Standard Care Is Not Enough | ALIV

Chronic non-healing wounds — wounds that have failed to progress through the normal healing sequence after twelve weeks of appropriate wound care — represent a significant clinical challenge in India's primary and secondary healthcare settings. The most common are diabetic foot ulcers, pressure ulcers (decubitus ulcers), venous leg ulcers, and post-surgical wounds in nutritionally compromised or immunosuppressed patients. These wounds fail to heal because the normal growth factor-mediated healing cascade is disrupted by the underlying biology of the condition producing them — and standard wound care alone cannot correct this growth factor deficit. ACT's concentrated growth factor delivery addresses the biological cause of healing failure rather than just the wound surface.

Why Chronic Wounds Fail to Heal

The normal wound healing sequence — haemostasis, inflammation, proliferation, remodelling — depends on a well-orchestrated growth factor cascade delivered by platelets, macrophages, and keratinocytes to the wound bed. In chronic wounds, this cascade is disrupted: wound fluid in chronic wounds is rich in matrix metalloproteinases (MMPs) that degrade growth factors before they can act; elevated inflammatory cytokines from the wound's bacterial burden maintain the inflammatory phase without transitioning to the proliferative phase; and in diabetic wounds, reduced VEGF production and microvascular disease prevent adequate neovascularisation of the wound bed. The result is a wound that is biologically "stuck" in the early inflammatory phase, unable to transition to the collagen synthesis and epithelialisation stages of healing.

ACT's growth factor payload — PDGF, VEGF, TGF-β, IGF-1 — directly counteracts these barriers: PDGF and TGF-β overcome the MMP-degraded growth factor environment by delivering a supraphysiological concentration; VEGF drives the angiogenesis that the diabetic microvascular disease has prevented; and the anti-inflammatory MSC paracrine signals shift the wound macrophage population from inflammatory (M1) to healing-supportive (M2) activation. These mechanisms are the same ones studied in the wound care PRP literature — ACT represents a richer cell source for the same regenerative principles. See: ACT for diabetes complications.

How is ACT administered to a wound?

Wound ACT is typically administered as peri-wound injection — the processed preparation is injected into the wound margins and bed, delivering growth factors to the healing tissue directly. For very large wounds, combination of peri-wound injection and systemic IV administration may be used to provide both local and systemic growth factor support. The preparation is not applied topically to the wound surface (where it would not penetrate adequately) but introduced into the wound tissue through targeted injection. This requires wound bed preparation — debridement of necrotic tissue and infection management — before ACT delivery to ensure the growth factors reach viable tissue rather than non-viable debris.

Are antibiotics needed before wound ACT?

Yes — wound infection must be adequately controlled before ACT. Introducing growth factors into an infected wound risks stimulating the infectious organisms alongside the healing tissue — and the inflammatory environment of an active infection suppresses the growth factor signalling. Wound swab culture and targeted antibiotic therapy, combined with surgical debridement where needed, precede ACT in infected wounds. The wound is reassessed at a clinically appropriate interval after infection control before ACT is introduced.